Bingbing Lu

547 total citations · 1 hit paper
10 papers, 242 citations indexed

About

Bingbing Lu is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Bingbing Lu has authored 10 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Surgery. Recurrent topics in Bingbing Lu's work include PI3K/AKT/mTOR signaling in cancer (4 papers), RNA modifications and cancer (3 papers) and Cancer-related Molecular Pathways (2 papers). Bingbing Lu is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (4 papers), RNA modifications and cancer (3 papers) and Cancer-related Molecular Pathways (2 papers). Bingbing Lu collaborates with scholars based in China, United States and United Kingdom. Bingbing Lu's co-authors include Zigang Dong, Kangdong Liu, Xuechao Jia, Kai Li, Yubo Zhai, Ziyue Liu, Fangfang Liu, Shuying Yin, Ann M. Bode and Yiu To Yeung and has published in prestigious journals such as Nature Communications, Cancer Research and Molecular Cancer.

In The Last Decade

Bingbing Lu

10 papers receiving 240 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

2024 92 citations Fangfang Liu, Kai Li et al. Molecular Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bingbing Lu China	8	181	62	60	36	21	10	242
Guang Tan China	9	160 0.9×	82 1.3×	48 0.8×	22 0.6×	36 1.7×	16	246
Athanasios Pagkalos Greece	7	202 1.1×	62 1.0×	102 1.7×	35 1.0×	21 1.0×	10	308
Shisheng Tan China	9	163 0.9×	53 0.9×	84 1.4×	30 0.8×	13 0.6×	18	253
Yuping Xie China	6	234 1.3×	32 0.5×	66 1.1×	31 0.9×	13 0.6×	10	296
Liye Fu China	11	216 1.2×	72 1.2×	91 1.5×	30 0.8×	19 0.9×	18	300
Cuifu Yu China	12	238 1.3×	91 1.5×	58 1.0×	43 1.2×	34 1.6×	15	300

Countries citing papers authored by Bingbing Lu

Since Specialization

Citations

This map shows the geographic impact of Bingbing Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bingbing Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bingbing Lu more than expected).

Fields of papers citing papers by Bingbing Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bingbing Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bingbing Lu. The network helps show where Bingbing Lu may publish in the future.

Co-authorship network of co-authors of Bingbing Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Bingbing Lu. A scholar is included among the top collaborators of Bingbing Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bingbing Lu. Bingbing Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Liu, Fangfang, Kai Li, Yubo Zhai, et al.. (2024). Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Molecular Cancer. 23(1). 148–148. 92 indexed citations breakdown →

2.

Liu, Xuejiao, Simin Zhao, Keke Wang, et al.. (2023). Spatial transcriptomics analysis of esophageal squamous precancerous lesions and their progression to esophageal cancer. Nature Communications. 14(1). 4779–4779. 28 indexed citations

3.

Jia, Xuechao, Penglei Wang, Chuntian Huang, et al.. (2023). Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth. Journal of Experimental & Clinical Cancer Research. 42(1). 97–97. 12 indexed citations

4.

Liu, Fangfang, Kyle Vaughn Laster, Xueli Tian, et al.. (2022). 3,3'-Diindolylmethane plus Eflornithine suppress DNA Replication and Cell Cycle in Esophageal Squamous Cell Carcinoma in vivo. Journal of Cancer. 13(8). 2607–2619. 1 indexed citations

5.

Li, Zhenzhen, Xin Li, Xinyu He, et al.. (2020). Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma. Frontiers in Pharmacology. 11. 9 indexed citations

6.

Ma, Xiaoli, Xiaomeng Xie, Bingbing Lu, et al.. (2020). 2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo. Journal of Experimental & Clinical Cancer Research. 39(1). 107–107. 15 indexed citations

7.

Zhang, Jing, Bingbing Lu, Jimin Zhao, et al.. (2020). Mefloquine Inhibits Esophageal Squamous Cell Carcinoma Tumor Growth by Inducing Mitochondrial Autophagy. Frontiers in Oncology. 10. 1217–1217. 19 indexed citations

8.

Yeung, Yiu To, Bingbing Lu, Shuying Yin, et al.. (2019). CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. Carcinogenesis. 41(3). 377–389. 34 indexed citations

9.

Yeung, Yiu To, et al.. (2019). Abstract 5293: Celf2 suppresses non-small cell lung carcinoma growth by inhibiting the prex2-pten interaction. Cancer Research. 79(13_Supplement). 5293–5293. 1 indexed citations

10.

Yeung, Yiu To, Shuying Yin, Bingbing Lu, et al.. (2018). Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization. EBioMedicine. 28. 51–61. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guang Tan Breakdown of academic impact, for papers by Athanasios Pagkalos Breakdown of academic impact, for papers by Shisheng Tan Breakdown of academic impact, for papers by Yuping Xie Breakdown of academic impact, for papers by Liye Fu Breakdown of academic impact, for papers by Cuifu Yu